Home>

Products

Submit Request Quote
 * Denotes Required Field.
Name:
 *
Company Name:
Phone:
Email:
 *
Message:
Request Quote
 
Out Of Stock image

Is currently out of stock, however if you enter your email address we will notify you when it comes back into stock!

Continue shopping Get Notified

Anti-PD1 [NIVOR4LALA]

Anti-PD1 [NIVOR4LALA]
Product Type: Therapeutics (In Vivo)
Format: Anti-PD1, 13B2, human variable region, rhesus IgG4 LALA Fc
Clone ID: [NIVOR4LALA]
RRID: AB_2819337
Common Names: Anti-PD1 [NIVOR4LALA] | Afamlixizumb | Anti-PD-1 (rhesus recombinant) | PR-4537 | NHP24
Target: CD279_PD1
Reactivity: Rhesus Macaque (Macaca mulatta) Human (Homo sapiens)
Applications: in vivo; blocking
Description:

NIVR4LALA: Rhesus recombinant (rhesus/human chimeric), effector-silenced IgG4-kappa anti-PD-1 antibody. Derived from nivolumab.
Modifications: None
Restrictions: No
Sponsor: NIAID
How to cite (Methods): The Anti-PD1 [NIVOR4LALA] antibody was engineered and produced by the Nonhuman Primate Reagent Resource (NIH Nonhuman Primate Reagent Resource Cat#PR-4537,RRID:AB_2819337).
How to cite (Acknowledgments): The Anti-PD1 [NIVOR4LALA] antibody used in this study was provided by the NIH Nonhuman Primate Reagent Resource (NIAID U24 AI126683).

Reagent cost, which is the actual cost of production, is recovered for some reagents. Please inquire if you have questions about reagent cost recovery. Purchase order or credit card is NOW REQUIRED for cost-recovered reagents.

You are not authorized to purchase this product. Please ensure you are logged into your account.

CAN'T FIND EXACTLY WHAT YOUR RESEARCH REQUIRES?

Request a Reagent:

Would you like to see an NHP-specific antibody developed through the program? Suggest a new reagent that would benefit the NHP community.

REQUEST A REAGENT

The Nonhuman Primate Reagent Resource (NHPRR) is a nonprofit laboratory established in 1999, and supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Office of Research Infrastructure Programs (ORIP).

Copyright © 2004-2024